Vir Biotechnology (VIR) Projected to Post Earnings on Thursday

Vir Biotechnology (NASDAQ:VIR - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 1st. Analysts expect Vir Biotechnology to post earnings of ($0.83) per share and revenue of $8.59 million for the quarter.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.85) by $0.09. The firm had revenue of $12.37 million during the quarter, compared to the consensus estimate of $8.14 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. On average, analysts expect Vir Biotechnology to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Vir Biotechnology Stock Down 1.2 %

VIR traded down $0.08 during trading on Tuesday, hitting $6.02. 110,524 shares of the stock were exchanged, compared to its average volume of 1,335,345. The stock has a fifty day moving average price of $6.83 and a two-hundred day moving average price of $8.05. Vir Biotechnology has a 1-year low of $4.95 and a 1-year high of $14.45. The firm has a market capitalization of $831.70 million, a P/E ratio of -1.53 and a beta of 1.14.

Insider Buying and Selling at Vir Biotechnology

In other Vir Biotechnology news, Director George A. Scangos sold 10,964 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $9.81, for a total value of $107,556.84. Following the transaction, the director now directly owns 708,295 shares of the company's stock, valued at approximately $6,948,373.95. This trade represents a 1.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Backer Marianne De sold 79,712 shares of Vir Biotechnology stock in a transaction dated Thursday, April 3rd. The stock was sold at an average price of $5.95, for a total value of $474,286.40. Following the transaction, the chief executive officer now owns 769,505 shares in the company, valued at approximately $4,578,554.75. This represents a 9.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 99,611 shares of company stock worth $663,525 over the last three months. Corporate insiders own 15.60% of the company's stock.

Analyst Upgrades and Downgrades

VIR has been the topic of a number of analyst reports. JPMorgan Chase & Co. lifted their price target on Vir Biotechnology from $10.00 to $14.00 and gave the company a "neutral" rating in a research note on Thursday, January 9th. Morgan Stanley upgraded shares of Vir Biotechnology from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $10.00 to $20.00 in a research note on Thursday, January 9th. Needham & Company LLC reiterated a "buy" rating and set a $19.00 price target on shares of Vir Biotechnology in a research report on Thursday, February 27th. The Goldman Sachs Group lowered their price target on Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating on the stock in a report on Thursday, April 17th. Finally, HC Wainwright reiterated a "buy" rating and set a $110.00 target price on shares of Vir Biotechnology in a research report on Friday, February 28th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $33.57.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).